REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 10th, 2018 • IntelGenx Technologies Corp. • Pharmaceutical preparations
This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the “Purchase Agreement”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 10th, 2018 • IntelGenx Technologies Corp. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 8, 2018, between IntelGenx Technologies Corp., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
WARRANTSSecurity Agreement • May 10th, 2018 • IntelGenx Technologies Corp. • Pharmaceutical preparations • Delaware
THIS IS TO CERTIFY THAT for value received __________________________or its assigns (the “Holder”) is the registered holder of the number of warrants (the “Warrants”) stated above and is entitled, for each whole Warrant represented hereby, to purchase one Share in the capital of IntelGenx Technologies Corp. (the “Corporation”) at any time from the date of issue hereof up to and including 5:00 p.m. (Toronto Time) on June 1, 2021 (the “Expiry Time”) at a price per Share equal to US$0.80, subject to adjustment hereunder (the “Exercise Price”), upon and subject to the following terms and conditions.
CANTONE RESEARCH, INC. PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • May 10th, 2018 • IntelGenx Technologies Corp. • Pharmaceutical preparations • Pennsylvania
This letter serves as our agreement (the “Agreement”) that IntelGenx Technologies Corp., a Delaware corporation (the “Issuer” or the “Company”) has engaged Cantone Research, Inc. (“CRI” or the “Placement Agent”) to act as the Company’s exclusive Placement Agent in the United States in connection with the proposed offering in the United States and Canada (the “Offering”) of units (the “Units”) at an offering price of $10,000, each Unit consisting of 7940 shares of the Issuer’s common stock (the “Unit Shares”), a $5,000 convertible note with a conversion price of $0.80 (together with all notes sold in the Offering, the “Notes” and, if converted, the “Conversion Shares”) and common stock purchase warrants representing the right to purchase 7690 shares of the Company’s common stock at an exercise price of $0.80 per share (the “Warrant Shares”) (the Units, the Notes, the Conversion Shares and the Warrant Shares are referred to collectively in this Agreement as the “Securities”) pursuant to
